THERAPY DOSSIER · th-b12df32c9632

Human adipose-derived stem cells coated with lipid-conjugated heparin (Lip-Hep/hADSC)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31026612 ↗2019Reported benefit

Significantly enhanced recovery of acute liver failure by liver targeted delivery of stem cells via heparin functionalization.

MouseChemical/toxinIntravenous administrationAfter acetaminophen challenge

Model: Acetaminophen (APAP)-induced acute liver failure

Heparin-coated stem cells showed greater hepatic delivery and retention and returned serum transaminases to normal faster than uncoated cells, with reduced inflammatory markers and improved liver histology.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…